中国医疗保健：在整体抛售潮中重新审视中国制药行业估值-China Healthcare-China Pharma - Revisiting Valuations amid Broader Sell-off

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the China Healthcare sector, specifically the pharmaceutical industry within the Asia Pacific region [1][2]. Core Insights and Arguments - Valuation Trends: - China large-cap HK-listed pharmaceutical companies are currently trading at a market-cap weighted-average forward P/E of 23x, which represents a 131% premium compared to the Hang Seng Index (HSI) [11]. - This premium has decreased from a peak of approximately 195% in August 2025, indicating a contraction in relative valuations [11]. - Valuations for A-share major pharmaceutical companies have also declined by approximately 20-30% from their mid-2025 peaks in terms of NTM P/E [11][14]. - Market Sentiment: - Despite a stable-to-improving domestic policy environment and ongoing globalization efforts, the sentiment in the market remains weak, which has led to discussions around relative P/E ratios [11]. - The report suggests that there is valuation support and limited yield impact, alongside concrete catalysts for quality pharmaceutical companies [11]. Additional Important Information - Historical Context: - The current P/E ratio is 0.4 standard deviations above the historical average since 2019, indicating that while valuations have contracted, they are still relatively high compared to historical norms [11]. - Geopolitical Factors: - The report acknowledges ongoing geopolitical uncertainties but emphasizes that these have not significantly impacted the domestic policy backdrop for the pharmaceutical sector [11]. - Analyst Ratings: - The report includes ratings for specific companies within the sector, indicating a generally positive outlook for several firms [66]. This summary encapsulates the key points from the conference call, highlighting the current state of the China pharmaceutical industry, valuation trends, market sentiment, and additional contextual factors that may influence investment decisions.